10:39 : AVI BioPharma tumbles on mixed study results -
BOSTON (MarketWatch) -- AVI BioPharma Inc. shares tumbled early Monday after the biotech group released mixed results from a Phase II study for its drug candidate eteplirsen in the treatment of Duchenne muscular dystrophy in boys. ...
04:48 : EU Patent Dispute Outcome Limits DMD Opportunity for AVI Biopharma -
Prosensa announced the outcome of the Opposition Division of the European Patent Office (EPO) ruling on dystrophin exon 51 skipping molecule. Wedbush Securities said the EPO decision, pending any appeal, may effectively prevent AVI BioPharma ...